The Beta Cell Responsiveness to Glucose-Dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier:
NCT00321321
First received: May 2, 2006
Last updated: October 1, 2008
Last verified: September 2008
Results First Received: September 29, 2008  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Sulfonylurea

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
May 2006 - March 2007, Outpatient clinic and advertisement

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
none

Reporting Groups
  Description
Sulfonylurea No text entered.

Participant Flow:   Overall Study
    Sulfonylurea  
STARTED     12  
COMPLETED     12  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sulfonylurea No text entered.

Baseline Measures
    Sulfonylurea  
Number of Participants  
[units: participants]
  12  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     11  
>=65 years     1  
Age  
[units: years]
Mean ± Standard Deviation
  55  ± 7.6  
Gender  
[units: participants]
 
Female     4  
Male     8  
Region of Enrollment  
[units: participants]
 
Denmark     12  



  Outcome Measures

1.  Primary:   Insulin Secretion   [ Time Frame: 0 - 90 minutes ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats


  More Information